Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1 Not yet recruiting

120 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT03293784 2026-03-30

TICIMEL

Phase 1 Completed

33 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT07000149 2026-03-10

eVOLVE-RCC02

Phase 3 Active not recruiting

1,116 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

Clinical Trials

KEYMAKER-U02

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

NEST-1

ENZYMELA

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

IMMUNO-FIT Observational Study

LuCa-MERIT-1

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

TICIMEL

eVOLVE-RCC02

Tremelimumab